Results with TECVAYLI®
TECVAYLI® was studied in 110 adults, 78% of whom had already been on at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
More than half of adults saw results with TECVAYLI® in the clinical trial
62% of people who took TECVAYLI® responded.
28% of people taking TECVAYLI® had a complete response or better to treatment. 29% of people taking TECVAYLI® had a very good partial response, and 5% had a partial response.
Median time to first response with TECVAYLI® was 1.2 months (response times ranged from 0.2 months to 5.5 months).
Talk to your doctor for more information about response.
Once you and your doctor have decided that TECVAYLI® is right for you, Janssen has resources to help support your treatment journey.
Personalized one-on-one support
Starting and staying on track with a new medication can feel overwhelming. A Janssen Compass® Care Navigator is here to help with free personalized one-on-one support over the phone throughout your treatment journey.
You will talk to the same Care Navigator on every phone call. They will help you in 3 key areas:
- Explore options that may help you pay for your medication
- Learn more about your cancer and Janssen medication
- Find resources for your practical and emotional needs while coping with cancer
Connect with a Care Navigator today
Call us at 844-628-1234, Monday through Friday, 8:30 AM – 8:30 PM ET.
Janssen Compass® is limited to education about your Janssen therapy, its administration, and/or your disease. It is intended to supplement your understanding of your therapy and is not intended to provide medical advice, replace a treatment plan from your doctor or nurse, or serve as a reason for you to start or stay on this medication.
